Saint Martin D Heres

The REMAP study aims to follow a cohort of 400 patients in around ten sleep centers in France and to collect clinical routine data. The objectives of this study are to investigate the effects of one-year management of OSA by CPAP or MAD on sleep architecture defined by objective macro and micro sleep architecture parameters using a sleep test device. sleep connected at home, to assess the quality of sleep and the quality of life reported by patients. The study will also allow us to define predictive factors for improving sleep quality during OSA treatment.

This study ai to accurately describe the chronic pelvic plan (CPP) from which transmasculine people can suffer, as well as their impact on quality of life, and to understand what are the obstacles and levers to the implementation of adapted care. Method: It is an observational, single-center, qualitative study. 10 to 15 trans individuals using testosterone therapy and having pelvic pain for at least 6 months, and that had appeared or changed since taking testosterone, will undergo a semi-structured interview. They will be recruited through community care associations, mailing lists and flyers. Results: This is a qualitative study aimed at accurately describing the symptoms of pelvic pain experienced by trans people thus we will do a qualitative analysis. QCAMAPS will be used for the coding step.

The goal of this clinical trial is to demonstrate that outpatient management for robotic-assisted radical prostatectomy is not inferior to inpatient management in terms of the occurrence of early post-operative complications. Researchers will compare outpatient robot-assisted radical prostatectomy to inpatient procedure. Participants will: * Visit the clinic after the operation once at 45 days, 6 months and once a year for up to 5 years for check-ups and tests. * Answer survey questions about urinary and erectil functions, stress and anxiety, satisfaction, quality of life for 6 months * Keep a diary to record procedures and treatments related to the care provided

Rotator cuff injury is a common pathology with a prevalence of 30% in the general population. The main symptom of a rotator cuff tear is pain. It can be sharp when it is accidental or manifests itself when the shoulder is solicited, frequently waking the patient at night. Conservative treatment may be offered in some patients, but in the event of prolonged pain or significant lesions, surgery is recommended. The gold standard treatment for rotator cuff tears is arthroscopic surgery. The anesthesia performed is a general anesthesia (GA) associated with a loco-regional anesthesia (LRA) of the shoulder. The injection of anesthetics into the brachial plexus before general anesthesia allows better control of postoperative pain. GA is given to patients after LRA, using a combination of hypnotic agents, curare and morphine, both for induction and maintenance of anaesthesia. GA has several advantages: patients with a rotator cuff tear do not experience pain during surgery. For the surgeon, the GA is comfortable since the patient remains motionless throughout the duration of the surgery. Nevertheless, this requires the availability of these drugs but also increases the risk of viral contamination, mainly due to COVID-19. During the first wave of the pandemic in March 2020, several countries in Europe were in need of curare and hypnotic agents. These specific drugs for anesthesia were administered in priority to patients requiring emergency GA or for carcinological surgery. Rotator cuff tears have therefore become irreparable, due to tendon retraction or fatty infiltration into the muscle, in patients with surgery postponed for several months. The recent development of ultrasound facilitates the realization of the LRA, allowing a better identification of the brachial plexus, for the injection of the anesthetic, resulting in a complete anesthesia of the shoulder. Even if the efficacy of LRA alone has already been described by several groups in non-GA shoulder surgeries, before 2020 it was rarely performed to repair rotator cuff tears under arthroscopy. Rotator cuff repair under LRA alone has been performed by several surgeons in France since COVID-19 and is now recommended by international experts. Particular attention should be paid to positioning the patient, maintaining cerebral perfusion and oxygenation. Methods of measuring cerebral perfusion or oxygenation are too slow for real-time assessment, so it is recommended to avoid general anesthesia to allow continuous clinical neurological assessment. The research hypothesis is that rotator cuff repair surgery under LRA alone is possible while maintaining the patient's blood pressure

The UroCCR project is a national kidney cancer registry and research network designed to address the specific challenges of renal cell carcinoma (RCC) management. While general cancer registries such as FRANCIM provide valuable surveillance data, most large-scale registries lack the depth of clinical, biological, and longitudinal follow-up information necessary to advance research and enable comprehensive analyses of kidney cancer outcomes. UroCCR was created in 2011 to meet this need. With over 21,000 cases collected from 58 centres across France, UroCCR is now one of the largest national databases dedicated to kidney cancer worldwide. The registry captures detailed clinical parameters, treatments and outcomes, complemented by patient-reported measures and socioeconomic data. Because management practices within UroCCR follow the recommendations of the French Association of Urology (AFU), the dataset closely reflects real-world practice and provides a reliable basis for comparison with national and European guidelines. Moreover, patient data can be reused across numerous studies, allowing researchers to explore multiple scientific questions without requiring new enrolments for each project. A distinctive strength of UroCCR is its integration of multiple research dimensions. Beyond clinical outcomes, it evaluates quality of life and the social and economic impact of kidney cancer. The registry is linked to annotated biobanking and national medico-administrative datasets, enabling translational studies and health services research. Additionally, UroCCR supports multiple ancillary studies, both retrospective analyses based on real-world data and prospective studies including randomised clinical trials or observational cohorts. The project benefits from robust governance structures, ensuring standardised procedures, data quality, and ethical oversight. It has also received various national and international labels, recognising its methodological rigour and excellence in research infrastructure. Digital innovations developed within the network, such as UroConnect® for perioperative monitoring and UroPredict machine learning models for recurrence and survival prediction, highlight its commitment to advancing care through new technologies. At the national level, projects such as CARARE are developing personalised treatment strategies, including a molecular tumour board for non-clear cell RCC. Internationally, UroCCR is strengthening collaboration through partnerships with the European Association of Urology and the European Robotic Urology Section, contributing to harmonised data collection and large-scale multicentre research. Ultimately, UroCCR functions as a dynamic research platform that unites clinicians, researchers, and patients around a shared infrastructure. By combining detailed clinical data with translational research, digital health tools, structured governance, recognised labels, and international partnerships, it aims to generate increasingly precise insights into RCC and to support the development of more effective, personalised treatment strategies in France and worldwide.